CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 199 resultados LastUpdate Última actualización 22/04/2021 [21:54:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 120 días/Published applications in the last 120 days



Página1 de 8 nextPage   por página


METHODS AND REAGENTS FOR DIAGNOSIS OF SARS-COV-2 INFECTION

NºPublicación: EP3809137A1 21/04/2021

Solicitante:

EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG [DE]
UNIV BERLIN CHARITE [DE]

Resumen de: EP3809137A1

The present invention relates to a method for diagnosing a SARS-CoV-2 infection comprising the step of detecting the presence or absence of an antibody to SEQ ID NO: 1, preferably IgA class antibody, in a sample from a subject, a method for the differential diagnosis of a coronavirus infection, a use of an antibody to SEQ ID NO: 1, preferably IgA class antibody for diagnosing a SARS-CoV-2 infection or for the differential diagnosis of a coronavirus infection, preferably for distinguishing between a SARS-CoV-2, MERS and NL63, 229E, OC43 and HKU1 infection, and a kit comprising a polypeptide comprising SEQ ID NO: 1 or a variant thereof, preferably coated to a diagnostically useful carrier and one or more, preferably all reagents from the group comprising an antibody to SEQ ID NO: 1, a washing buffer, a means for detecting the presence of an antibody, preferably IgA class antibody, preferably a secondary antibody binding specifically to IgA class antibodies, preferably comprising a detectable label, and a dilution buffer.

traducir

ARTIFICIAL INTELLIGENCE BASED SMART DETECTION OF LUNG DISEASE FROM CHEST X-RAY

NºPublicación: AU2020104159A4 15/04/2021

Solicitante:

D SIVAKUMAR R MR [IN]
DAHIYA AMAN DR [IN]
JAIN SHAFALI DR [IN]
KARTHIKEYAN R DR [IN]
KUMAR MANISH DR [IN]
MANAVALAN GOBINATH DR [IN]
PANIGRAHY ASISA KUMAR MR [IN]
PRAKASH MATTA DURGA DR [IN]
REDDY K BHASKAR DR [IN]
REDDY Y DASTAGIRI DR [IN]

Resumen de: AU2020104159A4

ARTIFICIAL INTELLIGENCE BASED SMART DETECTION OF LUNG DISEASE FROM CHEST X-RAY In recent years, multi fold improvement is viewed in the field of Artificial Intelligence hence plays a significant role in image classification especially classification of medical images. In specific Convolutional Neural Networks (CNN) belonging to Artificial Intelligence performs well in detection of several diseases such as heart disease, Dental diseases, Malaria and Parkinson's disease. CNN has significant vision in detection of lung disease utilizing the medical images of the patient such as X-rays. Lung disease is the basic symptom of the global pandemic disease COVID-19. This invention proposes a CNN model for the detection of lung disease where the model involves four layers namely input layers, convolutional layers, fully connected layers and output layers. The three layered two dimensional convolutional layers involves ReLu activation function along with Max pooling making the detection process easier by training the model using dataset. The proposed CNN model provides 97.4% of accuracy and 94.5% of precision. F1 score of the model is achieved as 97.60 and the curve area of Receiver Operating Characteristic (ROC) is obtained as 0.975. Figure 1. Layers Involved in Proposed Convolutional Neural Networks Algorithm ReLU >Sigmoid Ij+4 2 Infected efChannes Mi channels ix0 Normal Figure 2. Proposed SystemofLungDiseaseDetectionusingConvolutional Neural Networks Algorithm

traducir

SMART AND SAFE SHOPPING MART FOR COVID-19

NºPublicación: AU2021100310A4 15/04/2021

Solicitante:

AGARWAL AANCHAL [IN]
BATRA SHIVANI DR [IN]
GAHLOT AMIT [IN]
GOEL ANKIT [IN]
SACHDEVA SHELLY [IN]
SUKHIJA NAMRATA [IN]

Resumen de: AU2021100310A4

This invention relates to a machine and process of providing a touch less shopping mart to ensure safety in the situation of COVID-19. Particularly this invention relates to a machine for sanitizing and dispensing goods to the specific cart linked with a unique RFID tag. This invention also supports a machine for contactless inspection of the goods that customer wishes to purchase. This invention also supports the recommendation system for recommending goods based on the purchase history and current items added to the cart. Further, this invention also supports contactless bill payment. In this invention there is provided a machine comprising a customer registration interface generator, being provided to facilitate registration, biometric scanner, adapted to be connected to a database server, being provided to biometric sample needed to authenticate and verify the customer, a barcode reader, being provided to facilitate the customer with contactless inspection of product such as manufacturing date, expiry date, ingredients, nutrition information, net volume or weight, a RIFD tag reader, being provide to link the machine with a specific cart carrying the RIFD tag, a recommendation system, being provided to facilitate customer with recommendations of goods based on his/her purchase history and current products added to the cart, a navigation system, being provided to locate the recommended product in mart, a payment module, being provided to generate the bill of goods added to

traducir

INTELLIGENT ROBOTIC SYSTEM TO AUTOMATE SWAB TEST TO DETECT COVID-19 DISEASE

NºPublicación: AU2021100596A4 15/04/2021

Solicitante:

CHOUDHARY POOJA [IN]
JAIN PRAVEEN KUMAR [IN]
JAIN RITURAJ [ET]
KUMAR NISHANT [IN]
PANDEY BIPIN [IN]
SHARMA A K [IN]
SINGH JASPREET [IN]
SRIVASTAVA SANJAY [IN]
UPRETI KAMAL [IN]
VARGIS BINU KURIAKOSE [IN]

Resumen de: AU2021100596A4

INTELLIGENT ROBOTIC SYSTEM TO AUTOMATE SWAB TEST TO DETECT COVID-19 DISEASE The present invention discloses a method (300) and system (100) for automatic swab 5 collection. The apparatus reduces the chances of disease or virus to be communicated to medical staff which is engaged in the swab collection process. The present invention comprises of a robot arm (110) which has c swab collection stick on the tip which can be inserted in the nose of the entity whose head can be fixed on the adjustable head rest. The system (100) can be controlled wirelessly. The camera (170) coupled with the robot arm 10 (110) is used for calculating the distance of the entity from the robot arm (110). The control unit (160) then can facilitate the adjustment of the robot arm (110) according to the distance at which the entity is present. 130 "0 110 - Robot hand 120 - Swab test tube 200 130 - Adjustable chin rest 140 -Adjustable chin rest with fixed angle before swab test 150 - Patient 160 - SCST control unit 170 -Camera 180- Adjustable head rest in chin rest 190 - Clip to hold the forehead at fixed position 200 - Sanitizer dispenser FIG. 1 A system for automatic swab collection - 12 -

traducir

NUCLEIC ACID SEQUENCE EXPRESSING SARS-COV-2 VIRUS ANTIGEN PEPTIDE AND USE THEREOF

NºPublicación: EP3805392A2 14/04/2021

Solicitante:

GUANGZHOU N BIOMED LTD [CN]

WO_2021000968_A2

Resumen de: EP3805392A2

The present disclosure discloses nucleotide sequences as shown by SEQ ID NO: 1, SEQ ID NO: 2 and the nucleotide sequences having at least 90% homology therewith, which encode peptide antigens of SARS-CoV-2 virus. According to some embodiments of the present disclosure, the nucleotide sequences can be effectively expressed in human cells and produce the corresponding peptides, thereby inducing an immune-protective response accordingly. Thus, the nucleotide sequences of the present disclosure are expected to be developed as a vaccine against SARS-CoV-2 infection.

traducir

ADENOVIRUS CARRIER VACCINE USED FOR PREVENTING SARS-COV-2 INFECTION

NºPublicación: EP3804751A2 14/04/2021

Solicitante:

GUANGZHOU N BIOMED LTD [CN]

WO_2021000968_A2

Resumen de: EP3804751A2

The present disclosure discloses an adenovirus vectored vaccine for preventing SARS-CoV-2 infection, which comprises a nucleotide sequence as shown by SEQ ID NO: 1. According to some embodiments of the present disclosure, the vaccine comprises an S protein-coding nucleotide sequence which is easily expressed in human cells, and can produce more S proteins. The vaccine of the present disclosure is expected to be used as a recombinant viral vaccine for preventing SARS-CoV-2 infection. Some embodiments of the present disclosure have better safety.

traducir

Method of reducing insufflation gas leakage from a trocar

NºPublicación: US10973546B1 13/04/2021

Solicitante:

CLEARCAM INC [US]
CLEARAM INC [US]

Resumen de: US10973546B1

Disclosed herein are sealing devices and methods configured for improving sealing functionality with an engaged extension member of an apparatus. More specifically, disclosed herein are methods configured for improving insufflation gas containment in relation to trocars (and/or other related type of devices) that are used for enabling a surgical instrument such, for example, a laparoscope, to gain access to an abdominal cavity (or other body cavity). By providing for such improved insufflation gas containment, sealing devices as disclosed herein are particularly advantageous, desirable and useful in view of long-standing reasons for limiting insufflation gas leakage and in view of newly recognized reasons stemming from outbreak of COVID-19 disease for limiting insufflation gas leakage.

traducir

Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

NºPublicación: US10973908B1 13/04/2021

Solicitante:

BERMUDES DAVID GORDON [US]

Resumen de: US10973908B1

A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.

traducir

Coronavirus vaccine

NºPublicación: US10973909B1 13/04/2021

Solicitante:

PEPTC VACCINES LTD [GB]

Resumen de: US10973909B1

The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in an individual. The polypeptides and vaccines comprise T cell and/or B cell epitopes that are immunogenic in a high percentage of individuals in the human population.

traducir

MERS-CoV inhibitor peptides

NºPublicación: US10975126B1 13/04/2021

Solicitante:

KING FAISAL UNIV [SA]

Resumen de: US10975126B1

The MERS-CoV inhibitor peptides include a set of peptides designed by modification or mutation of a wild type MERS-CoV fusion protein. The MERS-CoV inhibitor peptides are capable of inhibition of MERS-CoV membrane fusion, and thereby may prevent or slow the spread of MERS-CoV infections. Thus, the MERS-CoV inhibitor peptides may be used in pharmaceuticals to prevent and/or treat MERS-CoV infection. The pharmaceuticals may be formulated to comprise at least one of the MERS-CoV inhibitor peptides and a carrier, or they may include one or more expression systems capable of promoting cellular expression of one or more MERS-CoV inhibitor peptides. The MERS-CoV inhibitor peptides may also be used as reagents for MERS-CoV inhibition assays as a standard or reference inhibitors.

traducir

Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

NºPublicación: US10975139B1 13/04/2021

Solicitante:

REGENERON PHARMA [US]

US_10954289_B1

Resumen de: US10975139B1

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

traducir

TARGETED DELIVERY OF MOLECULES USING IMPEDENCE-BASED MONITORING AT ELEVATED TEMPERATURES

NºPublicación: US2021101003A1 08/04/2021

Solicitante:

UNIV SOUTH FLORIDA [US]

Resumen de: US2021101003A1

A method and system for delivering a molecule to a specific area of a tissue by controlling temperature and impedance is presented. The method is generally comprised of applying heat to a biological structure, such as cells or tissues, to heat the biological structure to a preset temperature after which at least one electroporation pulse is administered to the biological structure. Impedance is measured as a feedback control mechanism after each pulse and pulse parameters are adjusted accordingly until desired impedance is reached. The system generally comprises an electroporation system capable of generating at least one pulse, measuring impedance and measuring temperature. The method may be used to deliver a molecule such as a vaccine or therapeutic to a biological structure, such as for prevention or treatment of SARS-CoV-2 infection.

traducir

BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE

NºPublicación: US2021102265A1 08/04/2021

Solicitante:

UNIV FLORIDA [US]

Resumen de: US2021102265A1

Described herein are bioaerosol detection systems and methods of use. In embodiments of bioaerosol detection systems and methods of use as described herein, systems and methods detect one or more coronaviruses and/or one or more influenza strains. In embodiments, coronaviruses according to systems and methods as described herein are SARS-CoV-2 coronavirus. In embodiments, influenza strains and/or particles according to the present disclosure are H1N1 influenza.

traducir

PHARMACEUTICAL KIT FOR COMBINATION THERAPY OF COVID-19 (SARS-COV-2) AND METHOD OF ITS APPLICATION

NºPublicación: RU2746161C1 08/04/2021

Solicitante:

OBSHCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU AVIRON OOO AVIRON [RU]

Resumen de: RU2746161C1

FIELD: pharmaceutical industry; medicine.SUBSTANCE: group of inventions relates to the pharmaceutical industry and medicine. Disclosed is a pharmaceutical kit for the combination therapy of COVID-19 (SARS-CoV-2). The pharmaceutical kit includes aprotinin (APR) in a therapeutically effective amount in the form of a finished medicinal product and favipiravir (FP) as a SARS-CoV-2 replication inhibitor in a therapeutically effective amount in the form of a finished medicinal product. The pharmaceutical kit ensures a therapeutically effective ratio of APR and the SARS-CoV-2 replication inhibitor placed in a package that protects the drugs from external factors. The pharmaceutical kit also includes instructions for use. Also disclosed is the use of the specified pharmaceutical kit for the combination therapy of COVID-19 (SARS-CoV-2).EFFECT: group of inventions provides a synergistic effect in treatment of COVID-19 as well as decreased recovery time of a patient with COVID-19.2 cl, 11 tbl, 4 ex

traducir

Method for reducing clinical false positives and negatives in the detection of SARS-CoV-2

NºPublicación: US10967368B1 06/04/2021

Solicitante:

MOORE TIMOTHY S [US]
MOORE CULLEN THOMAS [US]

Resumen de: US10967368B1

In embodiments there is described a method for reducing false positives and negatives in the detection of SARS-CoV-2 in suspected patients using mass spectroscopy employing the steps of mixing samples of collected saliva and nasopharyngeal secretions in a single sample container; adding universal transport medium to the mixed samples in said single sample container; transporting the single sample container at a temperature above 0° C. to a remote location; deactivation of viral content of the mixed sample; protein digestion of the mixed sample; concomitant separation of peptides, ionization by mass spectroscopy of the separated peptides, and comparison of peptide patterns to known SARS-CoV-2 peptides. Also set forth in an embodiment is a collection container for collecting saliva and/or sputum, as well as a swab member, with universal transport medium and/or virus inactivating agent housed in separate compartment communicable with sample compartment through a one-way valve.

traducir

COVID-19 (SARS-COV-2) COMBINATION THERAPY AND TREATMENT METHOD

NºPublicación: RU2745986C1 05/04/2021

Solicitante:

OBSHCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU AVIRON OOO AVIRON [RU]

Resumen de: RU2745986C1

FIELD: pharmaceutical industry; medicine.SUBSTANCE: group of inventions relates to the pharmaceutical industry and medicine. Disclosed is a combination method for the treatment of COVID-19 (SARS-CoV-2). According to the method, two drugs in therapeutically effective amounts and ratios are injected sequentially or simultaneously into the body of a patient with COVID-19. One of these drugs includes aprotinin and the other one includes favipiravir, which is a SARS-CoV-2 replication inhibitor. Also disclosed is a combination anti-coronavirus drug for use in the specified method.EFFECT: group of inventions provides a synergistic effect in treatment of COVID-19 (SARS-CoV-2) and can significantly shorten the treatment time and reduce the risk of unwanted side effects.2 cl, 10 tbl, 3 ex

traducir

ANTICORONAVIRUS THERAPEUTIC AGENT - SUBSTITUTED 7-HYDROXY-3,4,12,12A-TETRAHYDRO-1H-1,4OXAZINO3,4-CPYRIDO2,1-F1,2,4TRIAZINE-6,8-DIONE FOR THE PREVENTION AND TREATMENT OF COVID-19

NºPublicación: RU2745985C1 05/04/2021

Solicitante:

IVASHCHENKO ANDREJ ALEKSANDROVICH [RU]

Resumen de: RU2745985C1

FIELD: medicine/biotechnology.SUBSTANCE: invention relates to the use of a compound selected from (12aR)-7-hydroxy-12-[(10S)-6,7-difluoro-5,10-dihydrothieno[3,2-c][2]benzothiepin-10-yl]-3,4,12,12а-tetrahydro-1H-[1,4]oxazino [3,4-c]pyrido[2,1-ƒ][1,2,4]triazine-6,8-dione(1.2.1) or (12aR)-7-hydroxy-12-[(10S)-7,8-difluoro-4,9-dihydrothieno[2,3-c][2]benzothiepin-4-yl]-3,4,12,12а-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-ƒ][1,2,4]triazine-6,8-dione (1.5.1) as an anti-coronavirus agent for inhibiting 2019-nCoV coronavirus. EFFECT: proposed is a new application of a compound selected from (1.2.1) and (1.5.1) as an anti-coronavirus agent for inhibiting the 2019-nCoV coronavirus.3 cl, 4 ex

traducir

A METHOD FOR OBTAINING PLURIPOTENT STEM CELL-DERIVED AIRWAY BASAL-LIKE CELLS AND AN AIRWAY EPITHELIUM MODEL

NºPublicación: WO2021058956A1 01/04/2021

Solicitante:

NEWCELLS BIOTECH LTD [GB]

GB_2587802_A

Resumen de: WO2021058956A1

The present invention relates to methods for obtaining a substantially pure population of pluripotent stem cell-derived airway basal-like cells. It also relates to a method of obtaining an in vitro pluripotent stem cell-derived airway epithelium model, utilising the pluripotent stem cell-derived airway basal-like cells. The invention further relates to an in vitro airway epithelial model, or lung model, which can be used for disease modelling and/or drug screening and in particular to an in vitro model for SARS-CoV-2 infection and for screening for agents effective against infection with SARS-CoV-2 i.e. COVID-19 and methods of using the same.

traducir

NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS

NºPublicación: WO2021056098A1 01/04/2021

Solicitante:

KORANEX CAPITAL [CA]

US_2021085781_A1

Resumen de: WO2021056098A1

Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

traducir

ANTI-MERS-COV ANTIBODY AND USE THEREOF

NºPublicación: WO2021060837A1 01/04/2021

Solicitante:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
PASTEUR INSTITUT KOREA [KR]

Resumen de: WO2021060837A1

Provided is an anti-MERS-CoV antibody or an antigen-binding fragment thereof, and medical uses thereof.

traducir

METHOD FOR TREATMENT OF PATIENTS WITH NEW CORONAVIRUS INFECTION (COVID-19)

NºPublicación: RU2745774C1 31/03/2021

Solicitante:

MAROCHKOV ALEKSEJ VIKTOROVICH [BY]

Resumen de: RU2745774C1

FIELD: medicine, pulmonology.SUBSTANCE: invention relates to medicine, namely to to pulmonology and intensive care, and can be used to treat patients with new coronavirus infection (COVID-19). Said method according to the invention includes the diagnosis of infection by obtaining a positive test for the presence of RNA or IgM to SARS-CoV-2 or typical X-ray picture on a computed tomography of the thoracic organs. Then the patient is additionally prescribed acetylsalicylic acid 300 mg on the first day and 150 mg on days 2-21 of illness, clopidogrel 300 mg on the first day and 75 mg on days 2-21 and rivaroxaban 20 mg on days 1-21.EFFECT: use of the invention ensures an effective treatment of COVID-19 infection in patients of different age groups with minimal side effects.1 cl, 3 ex

traducir

METHOD FOR REHABILITATION OF PATIENTS WITH BRONCHOPULMONAL PATHOLOGY OF INFECTIOUS GENESIS

NºPublicación: RU2745697C1 30/03/2021

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE DOPOLNITELNOGO PROFESSIONALNOGO O [RU]

Resumen de: RU2745697C1

FIELD: medicine.SUBSTANCE: invention relates to medicine and namely to exercise therapy and physiotherapy. It particularly relates to the treatment of patients with bronchopulmonary pathology of infectious genesis and can be used at all stages of medical rehabilitation. Compression is carried out through a system of pneumatic cuff connections with a compression station. The operating modes of the device allow you to select the compression in pneumatic cuffs of 3 levels. Given the reports in the scientific literature about the need for a particularly gentle nature of the effects on the lung tissue of a patient with COVID-19, the chest compression mode and, therefore, the patient's activity increase gradually from the first to subsequent procedures. At the first procedure, the compression is set at the 1st level, at the 2nd procedure at the second level, at the 3rd procedure and subsequent levels, the compression corresponds to the 3rd level. The settings for the operation of the device allow you to change the duration of the compression and decompression phases of the chest. Influence with a low-frequency vibrator begins with 3 procedures. A low-frequency vibrator is installed in the projection of the legs of the diaphragm to the right and left of the spine at the costal arch level. The impact of the vibrator occurs synchronously with the operation of the compression station for pumping air into the system during the cycle of the selected duration. Before performing the proced

traducir

METHODS FOR PREPARING A GOLD NANOPARTICLE-BASED IMMUNOGEN FOR CARRYING OUT VACCINES AGAINST CORONAVIRUSES, SUCH AS SARS-COV-2

NºPublicación: RO134811A0 30/03/2021

Solicitante:

INSTITUTUL NAT DE CERCETARE DEZVOLTARE PENTRU FIZICA TEHNICA IFT IASI [RO]

Resumen de: RO134811A0

The invention relates to a method for preparing an immunogen based on gold nanoparticles for carrying out vaccines against coronaviruses. According to the invention, the method consists in the synthesis of gold nanoparticles (nAu), functioning as supports for the immobilization of antigens, by a hydrothermal method using tetrachloroauric acid and a coating agent based on aluminum citrate (cAl), resulting in nanostructures (nAu-cAl) of core-shell type having dimensions of 5...100 nm, which are used as such, after dialysis and sterilization, as immunogens, or are functionalized with immunogenic recombinant proteins specific to coronavirus infectious agents, at temperatures of 4...40°C for 1...24 h, followed by centrifugal separation, washing with ultrapure water, resuspension in phosphate saline buffer and/or 0.9% NaCl solution and, finally, filtration, resulting in a compound of nAu-cAl-proteins type with immunogenic properties, with increased biocompatibility and high agglomeration stability in highly saline environments, including the blood environment.

traducir

Methods of treating SARS Cov-2 virus with protocatechuic acid

NºPublicación: US10959969B1 30/03/2021

Solicitante:

JOHNSON LANNY L [US]

Resumen de: US10959969B1

The present disclosure provides methods for killing the SARS CoV-2 virus in mammals and treating the Coronavirus Disease-19 (Covid-19) in mammals including humans using compositions including protocatechuic acid. The present disclosure provides methods and pharmaceutical and nutraceutical compositions that reduce or substantially eliminate the SARS CoV-2 virus in mammals. In one embodiment, a method of treating a mammal with Covid-19 is provided comprising administering protocatechuic acid to a mammal in need of such treatment a therapeutically effective amount of a protocatechuic acid composition.

traducir

SARS-CoV-2 - Antibodies specifically binding to receptor-binding domain of SARS-CoV-2 spike protein and use thereof

Nº publicación: KR102233689B1 30/03/2021

Solicitante:

OSONG MEDICAL INNOVATION FOUND [KR]

Resumen de: KR102233689B1

본 발명은 SARS-CoV-2 스파이크 단백질(spike protein)의 수용체-결합 도메인(receptor binding domain, RBD)에 특이적으로 결합하는 항체 및 이의 이용에 관한 것이다. 보다 구체적으로 SARS-CoV-2 스파이크 단백질의 수용체-결합 도메인에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편, 이 항체 또는 이의 항원 결합 단편을 포함하는 SARS-CoV-2 감염 진단용 조성물, SARS-CoV-2 감염 진단용 키트, SARS-CoV-2 감염증의 예방 또는 치료용 약학적 조성물, 이 항체 또는 이의 항원 결합 단편을 이용하는 SARS-CoV-2 감염 진단을 위한 정보제공방법, 이 항체 또는 이의 항원 결합 단편을 암호화하는 폴리뉴클레오티드, 이 폴리뉴클레오티드를 포함하는 벡터 및 이 벡터로 형질전환된 세포에 관한 것이다. 본 발명의 항체 또는 이의 항원 결합 단편은 SARS-CoV-2 스파이크 단백질의 수용체-결합 도메인에 결합하여 SARS-CoV-2 스파이크 단백질과 숙주 세포의 ACE2 수용체 사이의 결합을 효율적으로 억제할 수 있어 SARS-CoV-2 감염의 진단, 예방 및 치료에 유용하며, 특히 RBD 변이체에도 결합할 수 있어 이러한 변이체에 대해서도 효과적이라는 장점이 있다. 이에 따라 본 발명의 조성물, 키트, 정보제공방법을 사용하면 SARS-CoV-2의 감염을 효과적으로 진단, 예방 또는 치료할 수 �

traducir

Página1 de 8 nextPage por página

punteroimgVolver